These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30517936)

  • 1. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
    Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
    Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
    BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
    Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
    BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
    VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
    Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
    Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
    Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
    BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
    Giridhar KV; Sanhueza C; Hillman DW; Alkhateeb H; Carlson R; Tan W; Costello BA; Quevedo F; Pagliaro L; Kohli M
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):431-437. PubMed ID: 29858590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
    Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
    BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
    D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
    Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
    Lilleby W; Paus E; Skovlund E; Fosså SD
    Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A: a useful biomarker in castration-resistant prostate cancer.
    Ploussard G; Rozet F; Roubaud G; Stanbury T; Sargos P; Roupret M
    World J Urol; 2023 Feb; 41(2):361-369. PubMed ID: 36527470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer.
    von Hardenberg J; Worst TS; Westhoff N; Erben P; Fuxius S; Müller M; Bolenz C; Weiss C; Heinrich E
    Oncol Res Treat; 2018; 41(10):627-633. PubMed ID: 30286478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
    Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
    Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
    Wang Y; Zhang H; Shen W; He P; Zhou Z
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.
    Muoio B; Pascale M; Roggero E
    Int J Biol Markers; 2018 Jan; 33(1):10-21. PubMed ID: 28885659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuroendocrine prostate cancer].
    Tritschler S; Erdelkamp R; Stief C; Hentrich M
    Urologe A; 2017 Nov; 56(11):1475-1484. PubMed ID: 29063171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.